New combination keeps inflammation down

Article

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery.

A new fixed combination of dexamethasone and netilmicin offers an effective and safe way to control ocular inflammation after cataract surgery, according to results of a study published in the January issue of Eye.

S. Russo and colleagues from the Medical department at SIFI S.p.A, Italy and the Military Hospital, Romania, enrolled 223 patients to receive either I mg/ml dexamethasone plus 3 mg/ml netilmicin (n=148) or 1 mg/ml dexamethasone plus 3 mg/ml tobramycin (Tobradex) (n=75), four times a day for seven days after cataract surgery. Efficacy and safety were analysed one and seven days postoperatively, in addition to a follow-up visit 142 days postoperatively. The extent of anterior chamber inflammation, measured by slit-lamp according to a standard scoring system, was used as the primary efficacy parameter.

At seven days both fixed combinations were equally effective in reducing inflammation and the dexamethasone/netilmicin combination demonstrated a good safety profile, with no evidence of poor local tolerance or adverse reactions.

It was concluded that this new fixed combination is both effective and safe as a treatment for ocular inflammation following cataract surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.